Omnicell (NASDAQ:OMCL) Cut to “Hold” at StockNews.com

StockNews.com lowered shares of Omnicell (NASDAQ:OMCL) from a buy rating to a hold rating in a research report report published on Friday morning.

Several other research firms have also issued reports on OMCL. Barclays lifted their target price on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Wells Fargo & Company increased their price objective on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. Bank of America restated a “neutral” rating and set a $57.00 target price (up from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. JPMorgan Chase & Co. boosted their target price on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research note on Friday, August 23rd. Finally, Benchmark reaffirmed a “buy” rating and set a $48.00 target price on shares of Omnicell in a research note on Wednesday, October 9th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $50.83.

Omnicell Trading Down 2.0 %

Shares of NASDAQ OMCL traded down $0.93 during mid-day trading on Friday, reaching $45.67. The company had a trading volume of 412,855 shares, compared to its average volume of 526,537. The business’s 50-day moving average is $44.20 and its 200-day moving average is $36.82. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -117.10, a price-to-earnings-growth ratio of 46.03 and a beta of 0.81.

Institutional Investors Weigh In On Omnicell

Several hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in shares of Omnicell by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after acquiring an additional 2,877 shares during the period. Pier Capital LLC acquired a new position in shares of Omnicell in the third quarter valued at approximately $5,859,000. SageView Advisory Group LLC purchased a new position in shares of Omnicell during the 3rd quarter worth $480,000. ArrowMark Colorado Holdings LLC boosted its stake in Omnicell by 27.1% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock worth $49,742,000 after buying an additional 243,353 shares during the last quarter. Finally, Verition Fund Management LLC purchased a new stake in Omnicell in the third quarter valued at approximately $388,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.